EZH2 and acute myeloid leukemia: Our previous studies showed that EZH2 overexpression and activation of Smo/Gli-1 pathway were related to the poor prognosis in AML patients, and Smo inhibitor effectively decreased leukemia growth and increased chemosensitivity [41–43].